UT College of Pharmacy and Pharmaceutical Sciences News

Posts Tagged ‘breast cancer’

NIH Award for Breast Cancer Research

Dr. L.M. Viranga Tillekeratne

Dr. L. M. Viranga Tillekeratne, associate professor of Medicinal and Biological Chemistry, received his first R15 award as a primary investigator from the National Institutes of Health. The award, in the amount of $449,000, will support graduate and undergraduate learning.
NIH Grant Number: 1 R15 CA213185-01A1
Principal Investigator: Tillekeratne, Viranga
Project Title: Novel Small Molecule Ferroptotic Compounds to Target Mesenchymal Breast Cancer and Breast Cancer Stem Cells
Award Issue Date: 12/25/2017 for $449,000


Collaborating for a Cure

Dr. Tiwari; Mary Kay Verhoff, director of the Women’s Wellness Center and Breast Cancer Coalition Awareness coordinator for St. Rita’s Medical Center, in Lima Ohio; and Angelique Nyinawabera, graduate student in Department of Pharmacology and Experimental Therapeutics.

Dr. Tiwari, Mary Kay Verhoff, director of the Women’s Wellness Center and Breast Cancer Coalition Awareness coordinator for St. Rita’s Medical Center, in Lima Ohio, and Angelique Nyinawabera

Dr. Amit K. Tiwari, assistant professor in the Department of Pharmacology and Experimental Therapeutics, was invited to present at the First Annual Breast Cancer Summit at St. Rita’s Medical Center in Lima, Ohio. The purpose of the summit was to improve breast cancer outcomes through early detection, survivorship support and health promotion, and participants included breast cancer survivors, primary health care personnel like nurses, technicians, physicians and pharmacists, and students and community members.

Triple-negative breast cancer (TNBC), which lacks three key cell surface receptors (ER,PR and HER2), is highly heterogeneous, aggressive, invasive, and metastatic. It recurs more frequently and offers a worse prognosis than other forms of breast cancer. TNBC also presents the highest health disparity, since it is three times more common among African-American women than among Caucasian women. Current chemotherapy, including targeted therapies, has limited value in the treatment of TNBC.

Dr. Tiwari discussed and provided information on current therapy options (taxanes, anthracyclines, PARP, platinums and other combinations) and future individualized therapy options for TNBC.

Angelique Nyinawabera, a graduate student in Department of Pharmacology and Experimental Therapeutics who is mentored by Dr. Tiwari, also attended the conference. Angelique’s research efforts are dedicated towards bridging the health disparity gap experienced by African-American women. Her dissertation focuses on targeting highly dysregulated mitochondrial genes to develop novel TNBC therapeutics.

This summit, which was designated for a maximum of 2.5 AMA PRA Category 1 Credits™, was sponsored by St. Rita’s Center for Continuing Education, which is accredited by the Ohio State Medical Association to provide continuing medical education for physicians. Dr. Tiwari believes this summit, and other similar programs that promote collaboration and discussion among patients, researchers and health care professionals, can improve care and outcomes tremendously, leading us toward a cure.